Multicomponent Reactions Upon the Known Drug Trimethoprim as a Source of Novel Antimicrobial Agents

Marina Pedrola1†, Marta Jorba2,3†, Eda Jardas1, Ferran Jardi1, Ouldouz Ghashghaei1, Miguel Viñas2,3* and Rodolfo Lavilla1*  

1Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain, 2Laboratory of Molecular Microbiology & Antimicrobials, Department of Pathology & Experimental Therapeutics, Medical School, Hospital de Llobregat, University of Barcelona, Barcelona, Spain, 3Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain

Novel antibiotic compounds have been prepared through a selective multicomponent reaction upon the known drug Trimethoprim. The Groebke-Blackburn-Bienaymé reaction involving this α-aminoazine, with a range of aldehydes and isocyanides afforded the desired adducts in one-step. The analogs display meaningful structural features of the initial drug together with relevant modifications at several points, keeping antibiotic potency and showing satisfactory antimicrobial profile (good activity levels and reduced growth rates), especially against methicillin-resistant Staphylococcus aureus. The new products may open new possibilities to fight bacterial infections.

Keywords: antibiotics, drugs, isocyanides, multicomponent reactions, resistant bacteria

INTRODUCTION

Trimethoprim (TMP, 1, Figure 1A) is a well-known antibiotic, present in the Model List of Essential Medicines from the World Health Organization. TMP is usually used in combination with Sulfamethoxazole (SMX) to treat lower urinary tract infections and acute invasive diarrhea/bacterial dysentery as first and second choice, respectively (WHO, 2017), respiratory infections in cystic fibrosis patients caused by Staphylococcus aureus, among others many infections. Lately, it has also been used for preventing infections from the opportunistic pathogen Pneumocystis carinii (Urbancic et al., 2018), which normally causes pneumonia in patients with AIDS. Both drugs act on the folic acid biosynthetic route by inhibiting two enzymes: dihydrofolate reductase (DHFR) and dihydropteroate synthetase, respectively. Folate needs to be synthesized by bacteria and it is crucial in the biosynthetic pathway of thymidine, essential in DNA synthesis. Hence, when used in combination, these antibiotics display a synergistic effect in inhibiting bacterial growth and leading to eventual cell death (Figure 1B) (Torok et al., 2009; Katzung et al., 2012).

The combination of sulfonamides and DHFR inhibitors has been clinically used since 1968 when it was first approved in the UK (Cody et al., 2008; Torok et al., 2009). Unfortunately, resistance emerged soon and has become widespread (Huovinen et al., 1995; Ventola, 2015). Nowadays, antibiotic resistance is one of the world’s most pressing public health problems with high morbidity and mortality rates (Centers for Disease Control and Prevention, 2017). Furthermore, finding active drugs to fight both multidrug resistant infections and organisms is becoming extremely challenging, as is often the case of methicillin-resistant Staphylococcus aureus (MRSA) and multidrug resistant Pseudomonas aeruginosa. In this context, the co-therapy with TMP and SMX turns out to be
ineffective to treat infections of a subset of bacteria with TMP-resistant DHFR enzymes (Heaslet et al., 2009).

Thus, the exploration of new synthetic compounds mimicking the structure and mechanism of action of conventional antimicrobial agents can be regarded as a main goal of this field of research. Such chemical entities would open new perspectives to reduce secondary effects and to enhance antimicrobial action and/or spectrum. Moreover, interaction between new molecules and conventional antimicrobials should be explored with the aim to find eventual synergistic activity.

So far, some research groups have introduced chemical variability at the trimethoxybenzyl residue of the TMP in order to optimize the drug and improve its properties, overall activity and tackle TMP-resistance issues (Scheme 1) (Zhou et al., 2013; Lombardo et al., 2016; Rashid et al., 2016), being able to find promising potent compounds against S. aureus and E. coli. However, in this work we will focus our efforts on modifying the 2,4-diaminopyrimidine moiety, through a selective multicomponent reaction (MCR), the Groebke-Blackburn-Bienaymé reaction (GBBR). In the past, changes at this part of the molecule have not been considered, as they involve key interactions in the recognition of the natural substrate at the DHFR active site; however, the situation could be otherwise in mutated enzymes. Furthermore, inspection of the PDB of the crystal structure of a TMP-DHFR complex shows room for structural changes at the pyrimidine moiety (Figure 1C) (Heaslet et al., 2009). These GBBR-type modifications will change the heterocyclic core of the drug into a more complex di- or tricyclic azine, and up to four diversity points, which will be introduced in a regioselective manner (Scheme 1). These transformations, involving a relevant structural change on the TMP original framework, strictly speaking cannot be considered as drug late stage functionalizations (Cernak et al., 2016), although share the same philosophy of the approach.

MCRs represent an alternative to the usual sequential multistep synthesis. They involve the reaction of three or more starting materials in a convergent way to yield an adduct, whose structure embodies the major part of the reactive materials in a one-pot reaction through a unified mechanism (Zhu et al., 2014). Specifically, these reactions bring high efficiency, simplicity and both atom and step economy. Thus, they are of interest in medicinal chemistry to assemble relevant, complex heterocycles with remarkable bioactivities and to speed up the Structure-Activity Relationship studies (Hulme, 2005; Akritopoulou-Zanze and Djuric, 2010; Domling et al., 2012; Slobbe et al., 2012; Zarganes-Tzitzikas and Doemling, 2014).

The GBBR (Scheme 2) is an isocyanide-based MCR yielding azine-fused imidazoles from readily available aldehydes (2), isocyanides (3) and amidine-type building blocks (1) (Bienaymé and Bouzid, 1998; Blackburn et al., 1998; Groebke et al., 1998). Several reviews have abstracted the main features of this MCR (Devi et al., 2015; Pericherla et al., 2015). This important transformation is massively used in medicinal chemistry, especially in drug discovery, because of the drug like character of the adduct (imidazo-azine), together with the power to decorate it with a wide range of structural diversity (Shaaban and Abdel-Wahab, 2016). These N-fused bicyclic imidazo-azines represent a special class of privileged scaffold found in several bioactive compounds and commercially available drugs, such as Zolpidem, Alpidem, Necopidem, Zolimidine, Divaplon, and
Minodronic acid (approved for treatments of insomnia, anxiety, peptic ulcers, epilepsy, osteoporosis, etc.) (Figure 2). It is also well-known that α-polyamino-polyazines are important aromatic polyheterocycles present in a wide variety of clinical drugs, such as the antibacterial drug Trimethoprim, the anticonvulsant drug Lamotrigine and the anticancer drug Methotrexate. Furthermore, specific GBBR adducts have been identified as active antibiotics through phenotypic analyses, addressing a variety of targets (Al-Tel and Al-Qawasmeh, 2010; Shukla et al., 2012; Semreen et al., 2013; Kumar et al., 2014). These facts back our project to modify TMP via GBBR processes to deliver potentially useful novel antibiotics, either improving the activity of the original drug upon DHFR or acting through independent mechanisms.
RESULTS AND DISCUSSION
Chemical Synthesis
In this context, we planned to develop a series of TMP derivatives through the GBBR by interaction of the original drug (TMP, 1) with a range of aldehydes (2) and isocyanides (3), and analyse the resulting MCR adducts as novel antibiotics, determining their potency, and efficiency, also considering their potential impact on resistant bacteria (Scheme 3).

The chemical modifications on TMP are based in our recent discoveries on GBBRs upon diaminopyrimidines, involving selective and multiple MCRs (Ghashghaei et al., 2018). In this way, the preparation of TMP analogs consisted in a regioselective mono-GBBR with an aldehyde/isocyanide pair, to yield derivatives 4; it is worth mentioning that a kinetic control justifies the preferential formation of the observed isomer. Furthermore, double GBBR processes upon TMP yield doubly substituted derivatives 5, with two equivalents of each reactant class (Scheme 3). The participation of a variety of Lewis acids catalyst is required to suitably generate and activate the imine intermediate and to achieve a moderate yield. In addition, standard flash chromatography purification was normally needed to afford the pure product. The designed analogs featured the N-fused bicyclic imidazo-azine scaffolds from the TMP reactant and displayed the variability points at substituents R₁, derived from the isocyanide input (3) and R₂ arising from the aldehyde reactant (2).

The processes worked in our TMP system as expected, yielding the corresponding products, showing the same reactivity and selectivity trends that were described in the unsubstituted diaminopyrimidine studies (Ghashghaei et al., 2018). For the initial screening, we prepared a series of TMP analogs featuring a variety of substituents on the imidazole amino group (R₁, being tert-butyl, 4-methoxyphenyl, cyclohexyl, and ethoxycarbonylmethyl) whereas at its carbon position a range of aromatic or alkyl substituents were introduced (R₂ being 4-chlorophenyl, α-, β-, or γ-pyridinyl, α-thienyl, methyl, and isopropyl). All the reactions were successful, yielding the mono-GBBR derivatives 4 and the doubly substituted-GBBR adducts 5 in acceptable yields (unoptimized). In this way, 12 new products (4a-4j and 5a-b) arising from the corresponding aldehyde/isocyanide combinations were suitably prepared as pure materials (Figure 3).

The connectivity of the first analog synthesized (4a) was assigned through two-dimensional NMR experiments: HSQC, HMBC and NOESY spectra (see Supplementary Material) and matched with the expected structure, displaying the regioselectivity previously described (Ghashghaei et al., 2018). The rest of derivatives showed the same spectroscopical trends and their structures were assigned by analogy. Furthermore, the doubly substituted GBBR adducts 5 synthetically derived from the corresponding precursors 4, then securing their identity.

We planned to incorporate an unsubstituted amino group in the imidazole ring of the novel derivatives 4 and 5 in order to favor their recognition by the DHFR active site, in line with the natural substrate. Then, we tackled the preparation of such compounds through the acidic removal of a tert-butyl group from a suitable precursor adduct coming from MCRs involving tert-butyl isocyanide. Precedent work by Krasavin et al. (2008) demonstrated that this transformation is feasible in GBBR
adducts. In this way, compounds 6a-6b and 7a were obtained as pure unsubstituted amino derivatives from tert-butyl precursors 4 and 5, after HBF₄ treatment (Scheme 4). All the synthesized compounds were suitably obtained in pure form, characterized and forwarded to microbiological analyses.

**Biological Analyses**

The Minimum Inhibitory Concentration (MIC) values of the 15 TMP analogs against control strains are shown in Table 1 (for details, see the Supplementary Material). Although all the compounds showed MIC values against *E. coli* ATCC 25922 and *S. aureus* ATCC 29213 higher than TMP, some of them were almost as potent as TMP (4c, 4f, 4h, 4i, 4j and 6a). *P. aeruginosa* PAO1 was found to be fully resistant to TMP, as well as to all new compounds. A preliminary inspection of the results showed that double GBBR adducts 5 lacked activity, probably meaning that they were unsuitable for binding to the target sites. Whereas for derivatives 4 some combinations were unproductive.
(especially the ones with aromatic and acetate $R^1$ substituents and $p$-chlorophenyl group at $R^2$ position), those featuring tert-butyl groups at $R^1$ and isopropyl, methyl, $\beta$, $\gamma$- (but not $\alpha$-) pyridyl, and $\alpha$-thienyl groups at $R^2$ were particularly favored. Moreover, comparing compounds 4d, 4g and 6b, we are able to confirm that the reduction of $R^1$ substituents size allowed to decrease the MIC. It is also worthy to emphasize that all compounds resulted to be more active on *E. coli* than on *S. aureus*; 4i, 4c, and 4f being the most potent ones. Thus, chemical modifications do not seem to limit the ability of the different new compounds to penetrate the outer membrane in Gram negative bacteria.

Almost all the new compounds acted synergistically with SMX as the control drug TMP did, against *E. coli* ATCC 25922 and *S. aureus* ATCC 29213 (Table 2); the latter species being much more sensitive to the SMX combination than to the treatment with the TMP-GBBR analogs alone. It also becomes apparent that nearly all the new compounds presented high activity against a set of clinical isolates of MRSA isolated from hospitalized or Cystic fibrosis (CF) patients. In CF patients, *Staphylococcus aureus* (and particularly MRSA) infection is the main challenge of antibiotic therapy, since the persistent infection caused by this bacterium is strongly associated with increased rates of decline in respiratory function and high mortality (Dolce et al., 2019). Thus, new approaches to fight this kind of bacterium are mandatory and should be based on new antimicrobials, most probably combined with conventional ones (Lo et al., 2018; Xhemali et al., 2019).

Again, derivatives 4c, 4f, 4h, 4i, 4j, and 6b were the most potent, but interestingly, some adducts which were not meaningful acting alone (Table 1), on SMX combination displayed a relevant potency (4a, 4d, 4e, 4g, and 6a). Disappointingly, no effect either of adducts alone or in combination with SMX was observed on *Pseudomonas aeruginosa* in any case, in line with the detected TMP activity. Particularly interesting are the activities against MRSA isolates as can be seen in Table 2, with many derivatives being as active as the TMP reference.

A relevant feature in the use of an antibiotic is its kinetic profile. Specifically, a fast reduction of the growth rates of the infective microorganism is of capital interest in therapeutics, arguably as important or more than the effective dose. Thus, the effect of TMP analogs in combination with SMX on the growth curves of *E. coli* ATCC 25922 and *S. aureus* ATCC 29213 was studied for the most interesting compounds (Figure 4 and Supplementary Material). Some differences were observed at subinhibitory concentrations of the antimicrobials (1/2 MIC and 1/4 MIC). In both tested bacteria, full inhibition occurred for derivatives 4g and 4i with SMX (1:20) at 1/2 the MIC value (Figures 4A,C,D). On the other hand, compounds 4g and 4f, at a concentration of 1/4 MIC, gave similar results than...
TMP at 1/2 MIC against *E. coli* ATCC 25922 (Figures 4A,B). In all the cases, significant reductions in the growth rates were observed when compared with the antimicrobial-free control, being comparatively better for some conditions than the TMP reference, especially compound 4i for long culture times (Figure 4D).

## CONCLUSION

The marketed antibiotic TMP (1) has been successfully modified by a GBB MCR with a range of commercially available aldehydes and isocyanides in selective processes yielding mono- or double-imidazo-azine adducts 4 and 5. A short synthetic (one or two steps) protocol allowed access to a focused library of 15 TMP analogs featuring a novel heterocyclic scaffold with a relevant degree of chemical diversity at selected positions, including hydrogen atoms, small alkyl groups, aromatic and heteroaromatic rings. Incidentally, this work shows the possibility of using known drugs as substrates for MCRs and, in this manner, opens new ways to develop novel chemical entities of biological interest from this unusual origin. Antimicrobial activity of the novel analogs has been assayed in Gram positive (*S. aureus*) and Gram negative (*E. coli*) microorganisms as well as on a bacterium considered the paradigm of resistance (*P. aeruginosa*). Despite the latter was resistant to all the new compounds, several mono-adducts 4 displayed MICs in the micromolar range against *E. coli* and *S. aureus*, what make us think that the TMP-derivatives bind to DHFR as well. The observed impact on growth kinetics allows us to conclude that the association of these new products with SMX exert a very similar effect than TMP itself. It is worthy to emphasize the excellent activities detected against MRSA strains. Given the reduced size of the focused chemset analyzed, and the relevant results found, we can conclude that the novel scaffold synthesized has potential to become a source for novel antibiotics. Further on going studies along these

### TABLE 1 | Minimum Inhibitory Concentration (MIC, µM) of TMP and the new GBBR analogs against *E. coli* ATCC 25922, *S. aureus* ATCC 29213, and *P. aeruginosa* PAO1.

|         | E. coli ATCC 25922 | S. aureus ATCC 29213 | P. aeruginosa PAO1 |
|---------|-------------------|----------------------|-------------------|
| TMP 1   | 0.43              | 13.78                | > 110.22          |
| 4a      | 16.13             | > 64.52              | > 64.52           |
| 4b      | > 67.01           | > 67.01              | > 67.01           |
| 4c      | 1.17              | 18.71                | > 74.85           |
| 4d      | 8.19              | > 65.50              | > 65.50           |
| 4e      | 5.19              | > 83.07              | > 83.07           |
| 4f      | 1.25              | 80.10                | > 80.10           |
| 4g      | 17.30             | > 69.18              | > 69.18           |
| 4h      | 2.14              | > 68.44              | > 68.44           |
| 4i      | 1.02              | 65.50                | > 65.50           |
| 4j      | 2.05              | 65.50                | > 65.50           |
| 5a      | > 45.60           | > 45.60              | > 45.60           |
| 5b      | > 56.66           | > 56.66              | > 56.66           |
| 6a      | 4.55              | > 72.75              | > 72.75           |
| 6b      | 2.46              | 78.73                | > 78.73           |
| 7a      | > 54.29           | > 54.29              | > 54.29           |

### TABLE 2 | Minimum Inhibitory Concentration (MIC, µM) of TMP and the new GBBR analogs in combination with Sulfamethoxazole (1:20) against *E. coli* ATCC 25922, *S. aureus* ATCC 29213, *P. aeruginosa* PAO1, *S. aureus* 8125304770, *S. aureus* 8139265926, *S. aureus* 8125255044, and *S. aureus* 8124825998.

|         | E. coli ATCC 25922 | S. aureus ATCC 29213 | P. aeruginosa PAO1 | S. aureus 8125304770 | S. aureus 8139265926 | S. aureus 8125255044 | S. aureus 8124825998 |
|---------|-------------------|----------------------|-------------------|----------------------|----------------------|----------------------|----------------------|
| TMP 1   | 0.11              | 0.43                 | 13.78             | 0.431                | 0.86                 | 0.22                 | 0.43                 |
| 4a      | 2.02              | 8.06                 | > 64.52           | 4.03                 | 8.06                 | 1.01                 | 4.03                 |
| 4b      | 67.01             | > 67.01              | > 67.01           | 67.01                | > 67.01              | > 67.01              | > 67.00              |
| 4c      | 1.17              | 4.68                 | 37.42             | 4.68                 | 9.36                 | 0.292                | 1.17                 |
| 4d      | 2.05              | 4.09                 | > 65.50           | 4.09                 | 4.093                | 1.02                 | 4.09                 |
| 4e      | 1.30              | 5.19                 | > 83.07           | 1.298                | 2.60                 | 0.65                 | 1.30                 |
| 4f      | 0.63              | 5.01                 | 40.05             | 0.63                 | 2.50                 | 0.63                 | 1.25                 |
| 4g      | 0.54              | 4.32                 | > 69.18           | 2.16                 | 8.66                 | 1.08                 | 4.32                 |
| 4h      | 0.27              | 2.14                 | 34.22             | 1.07                 | 1.07                 | 0.27                 | 1.07                 |
| 4i      | 0.13              | 2.05                 | 32.75             | 0.51                 | 1.02                 | 0.51                 | 1.02                 |
| 4j      | 0.26              | 2.05                 | 32.75             | 1.02                 | 2.05                 | 0.51                 | 1.02                 |
| 5a      | > 45.60           | > 45.60              | > 45.60           | > 45.60              | > 45.60              | > 45.60              | > 45.60              |
| 5b      | 28.33             | > 56.66              | > 56.66           | 28.331               | > 56.66              | 14.17                | 56.66                |
| 6a      | 2.27              | 9.09                 | > 72.75           | 2.27                 | 4.55                 | 1.14                 | 4.55                 |
| 6b      | 0.31              | 2.46                 | 78.73             | 1.23                 | 2.46                 | 0.62                 | 2.46                 |
| 7a      | > 54.29           | > 54.29              | > 54.29           | > 54.9               | > 54.29              | > 54.29              | > 54.29              |
lines tackle toxicity, the mechanism of action and bacterial resistance issues.

**DATA AVAILABILITY**

All datasets generated for this study are included in the manuscript and/or the Supplementary Files.

**AUTHOR CONTRIBUTIONS**

MP was responsible for designing and performing the initial experiments. EJ, FJ, OG, and RL performed the rest of the experimentation of the chemical section and analyzed the results. MJ designed and performed the microbiological experiments. MJ and MV analyzed the results of this section. All authors discussed the whole project and wrote the publication.

**FUNDING**

Financial support from the Ministerio de Economía y Competitividad-Spain (MINECO, CTQ2015-67870-P) and Generalitat de Catalunya (2017 SGR 1439) is gratefully acknowledged. The Microbiology group was financed by the Generalitat de Catalunya (GGC2017A-SGR-1488) and Marató TV3 (201C/2018) and its own funding.

**ACKNOWLEDGMENTS**

We thank Dr. Josep M. Sierra (U. Barcelona, IDIBELL) for useful suggestions and discussions. MV is a member of JIPAMR (Joint Programming Initiative on Antimicrobial Resistance) translocation-transfer and of ENABLE consortia. Clinical strains were kindly supplied by Servei de Microbiologia Hospital Vall d’Hebron (Barcelona).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2019.00475/full#supplementary-material
and pyrazines by a new three-component condensation. *Tetrahedron Lett.* 39, 3635–3638. doi: 10.1016/S0040-4039(98)00653-4

Centers for Disease Control and Prevention (2017). *Facts about Antibiotic Resistance and Antibiotic Prescribing: Attitudes, Behaviors, Trends and Cost*. Available at: http://www.cdc.gov/getsmart/community/about/fast-facts.html (accessed March 10, 2019).

Cernak, T., Dykstra, K. D., Tyagarajan, S., Krskab, P. V., and Shane, W. (2016). The medicinal chemist's toolbox for late stage functionalization of drug-like molecules. *Chem. Soc. Rev.* 45, 456–576. doi: 10.1039/C5CS00628G

Cody, V., Pace, J., Chisum, K., and Rosowsk, A. (2008). New insights into DHFR interactions: analysis of *Pneumocystis carinii* and mouse DHFR complexes with NAPDH and two highly potent 5-x-carboxy(alkoxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stack. *Proteins* 70, 311–319. doi: 10.1002/prot.21131

Devi, N., Rawal, R. K., and Singh, V. (2015). Diversity-oriented synthesis of fused-imidazole derivatives via Groebke-Blackburn-Bienaymée reaction: a review. *Tetrahedron* 71, 183–232. doi: 10.1016/j.tet.2014.10.032

Dolce, D., Neri, S., Grisotto, L., Campana, S., Ravenni, N., Miselli, F., et al. (2019). Methicillin-resistant *Staphylococcus aureus* eradication in cystic fibrosis patients: a randomized multicenter trial. *PLOS ONE* 14, 1–15. doi: 10.1371/journal.pone.0213497

Domling, A., Wang, W., and Wang, K. (2012). Chemistry and biology of multicomponent reactions. *Chem. Rev.* 112, 3083–3135. doi: 10.1021/cr200233r

Ghashghaei, O., Caputo, S., Sintes, M., Reves, M., Kielland, N., Estarellas, C., et al. (2018). Multiple multicomponent reactions: unexplored substrates, selective processes, and versatile chemotypes in biomedicine. *Chem. Eur. J.* 24, 14513–14521. doi: 10.1002/chem.201802877

Groebke, K., Weber, L., and Mehlin, F. (1998). Synthesis of imidazo[1,2-a]pyridines. *Synlett* 1998, 661–663. doi: 10.1055/s-1998-1721

Heaslet, H., Harris, M., Fahnoe, K., Sarver, R., Putz, H., Chang, J., et al. (2009). Structural comparison of chromosomal and exogenous dihydrofolate reductase from *Staphylococcus aureus* in complex with the potent inhibitor trimethoprim. *Proteins* 76, 706–717. doi: 10.1002/prot.22383

Hulme, C. (2005). “Applications of multicomponent reactions in drug discovery—lead generation to process development.” In *Multicomponent Reactions*, eds. J. Zhu and H. Bienaymée (Weinheim: Wiley-VCH), 311–341. doi: 10.1002/3527605118.ch11

Huovinen, P., Sundstrom, L., Svedberg, G., and Skold, O. (1995). Trimethoprim and sulfonamide resistance. *Antimicrob. Agents Chemother.* 39, 279–289. doi: 10.1128/AAC.39.2.279

Katzung, B. G., Masters, S. B., and Trevor, A. J. (2012). *Basic and Clinical Pharmacology. 12th Edn*. Oxford; San Francisco, CA: McGraw-Hill.

Krasavin, M., Tsirulnikov, S., Nikulnikov, M., Sandulenko, Y., and Bukhryakov, K. (2008). Tert-Butyl isocyanide revisited as a convertible reagent in the Groebke-Blackburn reaction. *Tetrahedron Lett.* 49, 7318–7321. doi: 10.1016/j.tetlet.2008.10.046

Kumar, M., Makhal, B., Gupta, V. K., and Sharma, A. (2014). *In silico* investigation of medicinal spectrum of imidazol-azines from the perspective of multitarget screening against malaria, tuberculosis and chagas disease. *J. Mol. Graph. Model.* 50, 1–9. doi: 10.1016/j.jmgm.2014.02.006

Lo, D., Muhlebach, M., and Smyth, A. (2018). Interventions for the eradication of meticillin-resistant *Staphylococcus aureus* (MRSA) in people with cystic fibrosis. *Cochrane Database Syst. Rev.* 21, 1–58. doi: 10.1002/14651858.CD009650.pub4

Lombardo, M. N., G-dayanandan, N., Wright, D. L., and Anderson, A. C. (2016). Crystal structures of trimethoprim-resistant DfrA1 rationalize potent inhibition by Propargyl-linked antifolates. *Infect. Dis.* 2, 149–156. doi: 10.1021/acssinfecdis.5b00129

Pericherla, K., Kaswan, P., Pandey, K., and Kumar, A. (2015). Recent developments in the synthesis of imidazo[1,2-a]pyridines. *Synthesis* 47, 887–912. doi: 10.1055/s-0034-1380182

Rashid, U., Ahmad, W., Hassan, S. F., Qureshi, N. A., Niaz, B., Muhammad, B., et al. (2016). Design, synthesis, antibacterial activity and docking study of some new trimethoprim derivatives. *Bioorganic Med. Chem. Lett.* 26, 5749–5753. doi: 10.1016/j.bmcl.2016.10.031

Seemren, M. H., El-Awady, R., Abu-Odeh, R., Saber-Ayad, M., Al-Qawasme, R. A., Chouaib, S., et al. (2013). Tandem multicomponent reactions toward the design and synthesis of novel antibacterial and cytotoxic motifs. *Curr. Med. Chem.* 20, 1445–1459. doi: 10.2174/09298671312110007

Shaaban, S., and Abdel-Wahab, B. F. (2016). Groebke-Blackburn-Bienaymée multicomponent reaction: emerging chemistry for drug discovery. *Mol. Divers.* 20, 233–254. doi: 10.1007/s11030-015-9602-6

Shukla, N. M., Salunke, D. B., Yoo, E., Mutz, C. A., Balakrishna, R., and David, S. A. (2012). Antibacterial activities of Groebke-Blackburn-Bienaymée-derived imidazo[1,2-a]pyridin-3-amines. *Bioorg. Med. Chem.* 20, 5850–5863. doi: 10.1016/j.bmcl.2012.07.052

Slobbe, P., Ruijter, E., and Orru, R. V. A. (2012). Recent applications of multicomponent reactions in medicinal chemistry. *Med. Chem. Commun.* 3, 1189–1218. doi: 10.1039/c2md20089a

Torok, E., Moran, E., and Cooke, F. (2009). *Oxford Handbook of Infectious Diseases and Microbiology*. Oxford: Oxford University.

Urbancic, K. F., Jerino, F., Phillips, E., Mount, P., Mahony, A., and Trubiano, J. (2018). Taking the challenge: a protocolated approach to optimize *Pneumocystis pneumonia* prophylaxis in renal transplant recipients. *Am. J. Transpl.* 18, 462–466. doi: 10.1111/ajt.14498

Ventola, C. L. (2015). The antibiotic resistance crisis: causes and threats. *Pharm. Ther.* 40, 277–283.

WHO (2017).20th WHO Model List of Essential Medicines. Essential Medicines and Health Products. Available online at: https://www.who.int/medicines/publications/essentialmedicines/20th_EMList2017.pdf?ua=1 (accessed March 10, 2019).

Xhemalci, X., Smith, J., Kebriaei, R., Rice, S., Stamper, K., Compton, M., et al. (2019). Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of *Staphylococcus aureus*. *J. Antimicrob. Chemother.* 74, 82–86. doi: 10.1093/jac/dky376

Zarganes-Tzitzikas, T., and Doemling, A. (2014). Modern multicomponent reactions for better drug synthesis. *Org. Chem. Front.* 1, 834–837. doi: 10.1039/C4QO00088A

Zhou, W., Scocchera, E. W., Wright, D. L., and Anderson, A. C. (2013). Antifolates as effective antimicrobial agents: new generations of trimethoprim analogs. *Med. Chem. Commun.* 4, 908–915. doi: 10.1039/c3md0104k

Zhu, J., Wang, Q., and Wang, M. (2014). *Multicomponent Reactions in Organic Synthesis*. 1st Edn. Weinheim: Wiley-VCH.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.